Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02270372
Recruitment Status : Completed
First Posted : October 21, 2014
Last Update Posted : May 17, 2018
Celldex Therapeutics
Information provided by (Responsible Party):
Seagen Inc. ( Cascadian Therapeutics Inc. )

Brief Summary:
This is a two-part Phase 1b, open-label study of ONT 10 administered in combination with varlilumab. Two different doses of varlilumab will be studied in combination with the single agent recommended dose of ONT 10. Intermediate and/or lower doses of varlilumab or ONT-10 may also be studied at the recommendation of the safety monitoring committee (SMC).

Condition or disease Intervention/treatment Phase
Advanced Breast Carcinoma Advanced Ovarian Carcinoma Biological: ONT-10, Varlilumab combination Phase 1

Detailed Description:

This is a two-part Phase 1b, open-label study of ONT 10 administered in combination with varlilumab. Two different doses of varlilumab will be studied in combination with the single agent recommended dose of ONT 10. Intermediate and/or lower doses of varlilumab or ONT-10 may also be studied at the recommendation of the safety monitoring committee (SMC). Treatment will be administered in cycles of 12 weeks each. All patients will receive a single dose of cyclophosphamide on Day -3. During Cycle 1, patients will receive ONT-10 administered SC once per week for 8 weeks followed by ONT-10 once every 6 weeks starting with Cycle 2, in combination with varlilumab administered IV once every 3 weeks x 3 doses, and then once every 6 weeks for cycles 2 through 5.

Each cohort will enroll an initial group of 6 evaluable patients with either breast or ovarian carcinoma. Initial enrollment into a cohort will be staggered, with the first patient treated in any new cohort to be followed for a minimum of two weeks for the occurrence of Unacceptable Toxicity prior to enrollment of the remaining 5 patients. Subsequent enrollment into a cohort may then continue without a staggered schedule until 6 patients treated are considered evaluable. Up to 24 additional evaluable patients may be enrolled and treated in Part 2 at the RD of varlilumab and ONT-10 identified in Part 1, including approximately equal numbers of patients with breast carcinoma (n~12) and ovarian carcinoma (n~12). Treatment in Part 2 will follow the same schedule as in Part 1.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Study of ONT 10 and Varlilumab in Patients With Advanced Ovarian Cancer or Breast Cancer
Study Start Date : November 2014
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: Drug Combination
The drug combination of ONT-10 and varilumab
Biological: ONT-10, Varlilumab combination

ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.

Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27.

Primary Outcome Measures :
  1. Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: Cycles of 12 weeks ]
    Assessment of the adverse event profile as an indication of overall safety and tolerability of the combination treatment with ONT-10 and varlilumab

Secondary Outcome Measures :
  1. Immune Response to MUC1 [ Time Frame: 8 weeks on a weekly basis, followed by every 6 weeks ]
    Determine the immune response of the drug combination of varlilumab and ONT-10 to MUC1 specific humoral and cellular responses.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be at least 18 years of age at the time of consent
  2. Life expectancy of at least 6 months, in the opinion of the investigator
  3. Have histologically confirmed breast or ovarian carcinoma
  4. Have evidence of persistent, recurrent, or progressive disease for which there is no known or established treatment available with curative intent, after at least one course of systemic therapy for locally advanced or metastatic disease , including chemotherapy, targeted therapy (small molecule or antibody based), or hormonal therapy
  5. Measurable or evaluable disease by RECIST 1.1
  6. ECOG performed status of 0 or 1
  7. Adequate hematologic function defined by:
  8. WBC count ≥ 3.0 x 103 cells/µL
  9. Lymphocyte count ≥ 0.8 x 103 cells/µL
  10. Platelet count ≥ 75 x 103 /µL, and
  11. Hemoglobin ≥ 9 g/dL
  12. Have renal and hepatic function as defined by:
  13. AST and ALT ≤ 2.5 X ULN
  14. Total bilirubin ≤ 1.5 X ULN. Patients with elevated bilirubin known to be due to Gilbert's disease may be enrolled after approval from the medical monitor, and
  15. Creatinine clearance ≥ 50 mL/min
  16. If female of child bearing potential, have a negative pregnancy test at screening
  17. If fertile male or female of child-bearing potential, agree to consistently use a highly effective method of birth control (including birth control pills, barrier device, or intrauterine device, abstinence or other methods prescribed by a licensed healthcare provider) from the time of consent through 70 days following the last dose of study drug
  18. Patient or a legally authorized representative of a patient must be able and willing to sign informed consent document that has been approved by an IRB

Exclusion Criteria:

  1. Has medical, social, or psychological factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures
  2. Is pregnant, breastfeeding, or planning a pregnancy
  3. Has received treatment with any systemic anticancer therapy, wide-field radiation, or experimental agent within 4 weeks of receiving cyclophosphamide on Day -3, with the exception of anticancer hormonal therapy, which may not be given within 2 weeks of receiving cyclophosphamide on Day -3. All residual toxicity related to prior anticancer therapies (excluding vitiligo, endocrinopathies on stable replacement therapy, alopecia and Grade 2 fatigue) must resolve to Grade 1 severity or less or return to baseline prior to receipt of study treatment.
  4. Has received treatment with focal radiotherapy within 2 weeks, or radiopharmaceuticals (e.g., strontium, samarium) within 8 weeks of receiving cyclophosphamide on Day -3
  5. Has untreated or uncontrolled CNS metastases, including patients who require glucocorticoid therapy for CNS metastases
  6. Has received prior treatment with ONT-10 or varlilumab, or prior treatment with other MUC1 vaccines or CD27-targeted agents
  7. Has active autoimmune disease or a documented history of autoimmune disease, or history of potential autoimmune syndrome that required systemic steroids or immunosuppressive medications, except for patients with vitiligo, endocrinopathies, type 1 diabetes, or patients with resolved childhood asthma/atopy or other syndromes which would not be expected to recur in the absence of an external trigger (e.g., drug-related serum sickness or post-streptococcal glomerulonephritis). Patients with mild asthma who require intermittent use of bronchodilators (such as albuterol) who have not been hospitalized for asthma in the preceding 3 years will not be excluded from this study.
  8. Has recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia, and/or other hereditary congenital immunodeficiencies
  9. Has any pre-existing medical condition requiring systemic chronic steroid or immunosuppressive therapy

    a) Inhaled corticosteroids for COPD or topical steroids are allowed

  10. Known to be positive for HIV, or to have active hepatitis B, or hepatitis C, or have active infection of any kind requiring systemic therapy
  11. Administration of any other vaccine ≤ 4 weeks of receiving cyclophosphamide on Day -3
  12. Underlying medical condition that, in the Investigator's opinion, will make the administration of study treatment hazardous or obscure the interpretation of toxicity determination of adverse events. This includes other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancer; or any other cancer from which the patient has been disease-free for at least 3 years.
  13. Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension (persistent systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg on antihypertensive medications) or arrhythmia, congestive heart failure (NYHA Class III or IV) related to primary cardiac disease, ischemic or severe valvular heart disease, or myocardial infarction within 6 months prior to the first dose of study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02270372

Layout table for location information
United States, Alabama
UAB Comprehensive Cancer Center
Birmingham, Alabama, United States, 35294
United States, Colorado
University of Colorado
Aurora, Colorado, United States, 80045
United States, New York
NYU Perlmutter Cancer Center
New York, New York, United States, 10016
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Cascadian Therapeutics Inc.
Celldex Therapeutics
Layout table for additonal information
Responsible Party: Cascadian Therapeutics Inc. Identifier: NCT02270372    
Other Study ID Numbers: ONT-10-104
First Posted: October 21, 2014    Key Record Dates
Last Update Posted: May 17, 2018
Last Verified: August 2016
Keywords provided by Seagen Inc. ( Cascadian Therapeutics Inc. ):
Advanced breast carcinoma
Advanced ovarian carcinoma
Phase 1b
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Breast Diseases
Skin Diseases
Endocrine Gland Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders